1037 GMT - Fevertree's partnership with Molson Coors in the U.S. represents a meaningful change in the U.K. mixer-maker's investment case, Goodbody analyst Fintan Ryan says in a note. On the positive side, Fevertree will receive cash up front to return to shareholders while Molson Coors will assume the operational costs and risks from executing the long-term growth potential of the brand in the U.S., the analyst says. However, Fevertree will also lose direct control of its largest market, a region where the company still is performing well and has the clearest strategy for market share growth, the analyst adds. Shares are up almost 25% at 814.0 pence, on track for their biggest intraday rise. (michael.susin@wsj.com)
(END) Dow Jones Newswires
January 30, 2025 05:39 ET (10:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。